imatinib mesylate has been researched along with Diffuse Large B-Cell Lymphoma in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, YF; Tang, HM | 1 |
| Abell, J; Christian, JB; Cullen, MR; Horwitz, RI | 1 |
| Cardenas, M; Cerchietti, L; Fan, L; Geng, H; Hajjar, KA; Leonard, JP; Luo, M; Melnick, A; Ruan, J; Wang, C; Yang, SN | 1 |
| Chute, JP; Himburg, HA | 1 |
| Cho, HS; Hyun, MS; Kim, MK; Koh, SA; Lee, HY; Lee, KH | 1 |
| Aloyz, R; Baker, K; Dirnhofer, S; Foulkes, W; Grygorczyk, C; Grygorczyk, R; Hollmann, CA; Martínez-Marignac, VL; Nadeau, J; Tzankov, A | 1 |
| Chu, DT | 1 |
| Alobeid, B; Bhagat, G; Fisher, JG; Flamm, MJ; Murty, VV; Schlaberg, R | 1 |
| Alkan, S; Amin, HM; Denning, MF; Ergin, M; Izban, KF; Martinez, RL; Saeed, S | 1 |
| Radich, JP | 1 |
4 review(s) available for imatinib mesylate and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
[Research Progress of C-Myc in Chronic Myelogenous Leukemia --Review].
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Proto-Oncogene Proteins c-myc | 2019 |
Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Examination; Chemoradiotherapy; Cyclophosphamide; Doxorubicin; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Piperazines; Positron-Emission Tomography; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vincristine; Whole Body Imaging | 2014 |
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Doxorubicin; Drug Delivery Systems; ErbB Receptors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Mutation; Neoplasms; Piperazines; Prednisone; Pyrimidines; Pyrroles; Remission Induction; Rituximab; Sunitinib; Vincristine | 2010 |
The promise of gene expression analysis in hematopoetic malignancies.
Topics: Animals; Benzamides; DNA Fingerprinting; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines | 2002 |
6 other study(ies) available for imatinib mesylate and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Medicine. (De)personalized medicine.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Genomics; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Myocardial Infarction; Piperazines; Precision Medicine; Pyrimidines | 2013 |
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Apoptosis; Benzamides; Biomarkers, Tumor; Blotting, Western; Cell Differentiation; Cell Proliferation; Gene Expression Profiling; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Mice; Mice, SCID; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Pericytes; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2013 |
Imatinib tackles lymphoma via the PDGFRβ+ pericyte.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Benzamides; Humans; Imatinib Mesylate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Neovascularization, Pathologic; Pericytes; Piperazines; Pyrimidines | 2013 |
Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Calcium Signaling; Cell Line, Tumor; Cell Separation; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Flow Cytometry; Humans; Imatinib Mesylate; Immunohistochemistry; Lymphoma, Large B-Cell, Diffuse; Microscopy, Fluorescence; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; src-Family Kinases; Thiazoles; Tissue Array Analysis | 2010 |
Chronic myeloid leukemia and HIV-infection.
Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Benzamides; CD4 Lymphocyte Count; Flow Cytometry; Follow-Up Studies; HIV Infections; HIV-1; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome; Viral Load | 2008 |
Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Caspases; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 5; Enzyme Inhibitors; Hodgkin Disease; Humans; Imatinib Mesylate; Immunohistochemistry; Lactams, Macrocyclic; Lymphoma, Large B-Cell, Diffuse; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinones; Receptor Protein-Tyrosine Kinases; Rifabutin; Translocation, Genetic; Tumor Cells, Cultured | 2001 |